GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » NetraMark Holdings Inc (XCNQ:AIAI) » Definitions » COGS-to-Revenue

NetraMark Holdings (XCNQ:AIAI) COGS-to-Revenue : 0.00 (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is NetraMark Holdings COGS-to-Revenue?

NetraMark Holdings's Cost of Goods Sold for the three months ended in Mar. 2024 was C$0.00 Mil. Its Revenue for the three months ended in Mar. 2024 was C$0.22 Mil.

NetraMark Holdings's COGS to Revenue for the three months ended in Mar. 2024 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. NetraMark Holdings's Gross Margin % for the three months ended in Mar. 2024 was N/A%.


NetraMark Holdings COGS-to-Revenue Historical Data

The historical data trend for NetraMark Holdings's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NetraMark Holdings COGS-to-Revenue Chart

NetraMark Holdings Annual Data
Trend Sep20 Sep21 Sep22 Sep23
COGS-to-Revenue
- - - -

NetraMark Holdings Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

NetraMark Holdings COGS-to-Revenue Calculation

NetraMark Holdings's COGS to Revenue for the fiscal year that ended in Sep. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0 / 0.089
=0.00

NetraMark Holdings's COGS to Revenue for the quarter that ended in Mar. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0 / 0.222
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NetraMark Holdings  (XCNQ:AIAI) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

NetraMark Holdings's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 0 / 0.222
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


NetraMark Holdings COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of NetraMark Holdings's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


NetraMark Holdings (XCNQ:AIAI) Business Description

Traded in Other Exchanges
Address
1655 Dupont Street, Suite 101, Toronto, ON, CAN, M6P 3T1
NetraMark Holdings Inc is focused on the application of a totally unique Artificial Intelligence (AI) / Machine Learning (ML) solution targeted at the pharmaceutical industry in order to de-risk clinical trials. NetraMark has a proprietary technology that is capable of cutting through the combinatorial complexity that comes with dealing with heterogeneous patient populations to extract precisely defined personas of patients with respect to placebo and drug response, in addition to tolerability and adverse events. By using the client's own contemporaneous data, and having the capacity to learn from small data, the NetraAI tech extracts these personas to equip pharmaceutical companies with strategies to optimize their next trials for success.
Executives
Andrew Parks Director

NetraMark Holdings (XCNQ:AIAI) Headlines

No Headlines